



## May 2018 Newsletter

Volume 6 Issue 5

### A Letter from the Founder, Dr. Christine Brezden-Masley

Dear CCTC Members,

Thank you for your continued support of the website and use of the e-referral clinical trial portal.

Our goal is to showcase as many oncology clinical trials that are open in Ontario, providing ready access for your patients.

We welcome and encourage suggestions so we can continue to improve the service of the CCTC. Simply please send us an email.

Sincerely,

**Dr. Christine Brezden-Masley**

### A Letter from the Project Manager, Alexandra Moskalewicz

Hello CCTC members,

Please contact me at [comettrials@smh.ca](mailto:comettrials@smh.ca) if I can be of any assistance in posting new trials, or removing postings for trials that have now closed to recruitment at your centre.

Feel free to share this newsletter with any colleagues that may be interested, as we are always happy to have new members join our network!

Kind Regards,

**Alexandra Moskalewicz**

## ARTICLE RECOMMENDATION

### Barriers to participation in clinical trials: a physician survey

Mahmud A., Zalay O., Springer A., Arts K., Eisenhauer E.

DOI: 10.3747/co.25.3857 Published April 2018

**BACKGROUND:** Clinical trials are vital for evidence-based cancer care. Oncologist engagement in clinical trials has an effect on patient recruitment, which in turn can affect trial success. Identifying barriers to clinical trial participation might enable interventions that could help to increase physician participation.

**METHODS:** To assess factors affecting physician engagement in oncology trials, a national survey was conducted using the online SurveyMonkey tool. Physicians associated with the Canadian Cancer Clinical Trials Network and the Canadian Cancer Trials Group were asked about their specialty, years of experience, barriers to participation, and motivating interventions, which included an open-ended question inviting survey takers to suggest interventions.

**RESULTS:** The survey collected 207 anonymous responses. Respondents were predominantly medical oncologists (46.4%), followed by radiation oncologists (24.6%). Almost 70% of the respondents had more than 10 years of experience. Significant time constraints included extra paperwork (77%), patient education (54%), and extended follow-up or clinic visits (53%). Timing of events within trials was also a barrier to participation (55%). Most respondents favoured clinical work credits (72%), academic credits (67%), a clinical trial alert system (75%), a regular meeting to review trial protocols (65%), and a screening log to aid in patient accrual (67%) as motivational strategies. Suggested interventions included increased support staff, streamlined regulatory burden, and provision of greater funding for trials and easier access to ancillary services.

## TRIALS SNAPSHOT

Trial Type	Any Malignancy	Breast	CNS	GI	GU	GYN	Head & Neck	Heme	Lung	Mel	Skin	Total
<b>Imaging Study</b>		1	1		2			1				5
<b>Observational</b>	1	3				1		1				6
<b>Prevention</b>				1				1				2
<b>Radiation</b>	1	1		3	6		1		6			18
<b>Supportive Care</b>	1	5										6
<b>Surgical Therapy</b>		1			1	1	1					4
<b>Systemic Therapy</b>	2	7		16	20	4	3	9	9	3	2	75
<b>Therapeutic</b>					2			2				4
<b>TOTAL</b>	5	18	1	20	31	6	5	14	15	3	2	120



## May 2018 Newsletter

Volume 6 Issue 5

### TRIALS OF THE MONTH

Type	Acronym	Study Title	Description	Site(s)
Breast	<a href="#">PET ABC</a>	Impact of 18F-FDG PET-CT Versus Conventional Staging in the Management of Patients Presenting With Clinical Stage III Breast Cancer	<ul style="list-style-type: none"> <li>Any HER2</li> <li>Imaging Study</li> </ul>	Odette Cancer Centre
GU	<a href="#">NRG GU003</a>	A Randomized Phase III Trial of Hypofractionated Post-prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-prostatectomy Radiation Therapy (COPORT)	<ul style="list-style-type: none"> <li>Prostate Cancer</li> <li>Radiation Therapy</li> </ul>	London Health Sciences Centre
Heme	<a href="#">SGI-110-07</a>	A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) Versus Treatment Choice in Adults With Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated With Hypomethylating Agents	<ul style="list-style-type: none"> <li>MDS or CMML</li> <li>Systemic Therapy</li> </ul>	Royal Victoria Regional Health Centre
GYN	<a href="#">ORZORA</a>	An Open Label, Single Arm, Multicentre Study to Assess the Clinical Effectiveness and Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed Somatic or Germline BRCA Mutated Ovarian Cancer Patients Who Are in Complete or Partial Response Following Platinum Based Chemotherapy	<ul style="list-style-type: none"> <li>Ovarian Cancer</li> <li>Systemic Therapy</li> </ul>	London Health Sciences Centre
Lung	<a href="#">ATLANTIS</a>	Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) Versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line	<ul style="list-style-type: none"> <li>Small-Cell Lung Cancer</li> <li>Systemic Therapy</li> </ul>	Southlake Regional Health Centre
Skin	<a href="#">R2810-ONC-1620</a>	A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1, in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy	<ul style="list-style-type: none"> <li>Systemic Therapy</li> <li>Advanced Basal Cell Carcinoma</li> </ul>	Odette Cancer Centre London Health Sciences Centre
GI	<a href="#">HIMALAYA</a>	A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma	<ul style="list-style-type: none"> <li>Unresectable HCC</li> <li>Systemic Therapy</li> </ul>	Odette Cancer Centre



[Click here to NOMINATE your trial for Trials of the Month!](#)



## MEMBERSHIP UPDATES

**287 members**  
**31 institutions**  
**120 accruing trials**



## ACKNOWLEDGEMENTS

The CCTC has been funded by unrestricted educational grants from the following supporters:



## CONTACT US

Do you have any questions, feedback, suggestions? Please do not hesitate to contact us.

30 Bond Street  
Toronto, ON Canada  
M5B 1W8

[comettrials@smh.ca](mailto:comettrials@smh.ca)  
(416) 809-3915

 [@COMET\\_Trials](https://twitter.com/COMET_Trials)  
[www.comettrials.com](http://www.comettrials.com)

## INSTITUTIONS

Institution	Location	Members	Trials
Cambridge Memorial Hospital	Cambridge	3	3
Grand River Hospital	Waterloo	9	1
Humber River Regional Hospital	Toronto	5	2
Kingston General Hospital	Kingston	4	18
Juravinski Cancer Centre	Hamilton	7	-
Lakeridge Health Corporation	Oshawa	21	-
London Health Sciences Centre	London	9	60
Mackenzie Health Hospital	Richmond Hill	6	-
Markham Stouffville Hospital	Markham	4	1
Michael Garron Hospital	Toronto	7	
Mount Sinai Hospital	Toronto	2	2
North York General Hospital	Toronto	15	6
Odette Cancer Centre/Sunnybrook	Toronto	61	51
Ontario Institute for Cancer Research	Toronto	4	-
Ottawa Hospital	Ottawa	2	-
Princess Margaret Cancer Centre	Toronto	26	1
Quinte Health Care	Belleville	1	-
Rouge Valley Health System	Ajax	3	-
Royal Victoria Regional Health Centre	Barrie	24	16
Scarborough General Hospital	Toronto	3	-
Southlake Regional Health Centre	Newmarket	19	6
St. Joseph's Health Centre	Toronto	4	-
St. Joseph's Healthcare	Hamilton	4	-
St. Michael's Hospital	Toronto	14	3
Sudbury Regional Hospital	Sudbury	1	-
Thunder Bay Regional	Thunder Bay	2	-
Toronto General Hospital	Toronto	3	1
Trillium Health Partners	Mississauga	17	-
William Osler Health Systems	Brampton	4	-
Windsor Regional Hospital	Windsor	2	-
Wingham and District Hospital	Wingham	1	-